Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 12 tags : Phase 2 save search
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting
Published: 2021-04-12 (Crawled : 14:00) - biospace.com/
KTRA | $0.1374 3.54% 3.42% 5.8M
|
Distribution Services
|
| O: 2.15%
H: 2.11%
C: -9.47%
phase 2 clinical trials cancer research trial
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
Published: 2021-04-12 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.08%
phase 1 phase 3 phase 2
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
Published: 2021-04-12 (Crawled : 13:00) - biospace.com/
KNSA | $17.85 0.96% 0.95% 370K
|
Health Technology
|
| O: 0.0%
H: 0.11%
C: -8.71%
covid phase 2 positive results positive results trial
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-04-12 (Crawled : 13:00) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: -0.52%
H: 1.24%
C: -1.66%
ALLO | $3.04 -9.79% -10.86% 2.1M
|
Health Technology
|
| O: 1.31%
H: 1.26%
C: -11.04%
phase 1 phase 3 phase 2
Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers
Published: 2021-04-12 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -1.68%
H: 2.54%
C: -5.2%
treatment phase 1 positive cancer trial rtx-321 phase 3 phase 2
Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome
Published: 2021-04-12 (Crawled : 12:00) - anavex.com
AVXL | $3.4 -7.61% -8.24% 2M
|
Health Technology
|
| O: -0.07%
H: 1.17%
C: -8.85%
phase 2 phase 2/3 results life science trial anavex®2-73 anavex syndros rett syndrome
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Published: 2021-04-12 (Crawled : 12:00) - biospace.com/
SAGE | $14.0 8.11% 7.5% 2.3M
|
Health Technology
|
| O: -1.24%
H: 0.19%
C: -1.3%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.32%
H: 0.36%
C: -1.69%
phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.